Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1146/ANNUREV-PATHOL-020117-043617 | ||||
| Año | 2018 | ||||
| Tipo | revisión |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing prevalence of this disease and of its aggressive form nonalcoholic steatohepatitis (NASH) will require novel therapeutic approaches based on a profound understanding of its pathogenesis to halt disease progression to advanced fibrosis or cirrhosis and cancer. The pathogenesis of NAFLD involves a complex interaction among environmental factors (i.e., Western diet), obesity, changes in microbiota, and predisposing genetic variants resulting in a disturbed lipid homeostasis and an excessive accumulation of triglycerides and other lipid species in hepatocytes. Insulin resistance is a central mechanism that leads to lipotoxicity, endoplasmic reticulum stress, disturbed autophagy, and, ultimately, hepatocyte injury and death that triggers hepatic inflammation, hepatic stellate cell activation, and progressive fibrogenesis, thus driving disease progression. In the present review, we summarize the currently available data on the pathogenesis of NAFLD, emphasizing the most recent advances. A better understanding of NAFLD/NASH pathogenesis is crucial for the design of new and efficient therapeutic interventions.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Arab, Juanpablo | Hombre |
Pontificia Universidad Católica de Chile - Chile
Mayo Clin - Estados Unidos Mayo Clinic - Estados Unidos Escuela de Medicina - Chile |
| 2 | ARRESE-JIMENEZ, MARCO ANTONIO | Hombre |
Pontificia Universidad Católica de Chile - Chile
Escuela de Medicina - Chile |
| 3 | Trauner, Michael | Hombre |
Med Univ Vienna - Austria
Medizinische Universitat Wien - Austria |
| 4 | Galli, SJ | - | |
| 5 | Abbas, AK | - | |
| 6 | Aster, JC | - |
| Fuente |
|---|
| Fondo Nacional de Ciencia y Tecnología |
| Comisión Interministerial de Ciencia y Tecnología |
| Austrian Science Fund |
| Fondo Nacional de Ciencia y TecnologÃa |
| AASLD/LIFER |
| AASLD Foundation |
| Comisión Interministerial de Ciencia y TecnologÃa |
| Vienna Science and Technology Fund |
| Austrian Science Foundation |
| Agradecimiento |
|---|
| The authors would like to thank Dr. Nicolás Triantafilo for his excellent work drawing the figures of this article. This work was funded, in part, by grants F3008-B19 and F3517-B20 from the Austrian Science Foundation (FWF) and grant LS12-08 from the Vienna Science and Technology Fund (M.T.); grant 1150327 from the Fondo Nacional de Ciencia y Tecnología de Chile (M.A.); grant PIA/Basal PFB12 from the Comisión Nacional de Investigación, Ciencia y Tecnología; and by an AASLD/LIFER Clinical and Translational Research Fellowship in Liver Diseases from the AASLD Foundation (to J.P.A.). |